Loop diuretics have anxiolytic effects in rat models of conditioned anxiety

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Krystal, Andrew D ^a   Sutherland, Janice ^b   Hochman, Daryl W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; FUROSEMIDE; POTASSIUM CHLORIDE COTRANSPORTER; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; ANXIOLYTIC AGENT; LOOP DIURETIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; FEAR; FOOTSHOCK; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; RAT; REARING; STARTLE REFLEX; STIMULUS RESPONSE; TRANQUILIZING ACTIVITY; ANIMAL; DISEASE MODEL; LONG EVANS RAT;

RATTUS;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BUMETANIDE; DISEASE MODELS, ANIMAL; FUROSEMIDE; MALE; RATS; RATS, LONG-EVANS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84859722700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035417     Document Type: Article

References (52)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the united states. results from the national comorbidity survey. Archives of General Psychiatry 51: 8-19.
2. Lépine J, (2002) The epidemiology of anxiety disorders: prevalence and societal costs. The Journal of Clinical Psychiatry 63 (Suppl 14): 4-8.
3. Hicks D, Cummings J Thomas, Epstein SA, (2010) An approach to the patient with anxiety. The Medical Clinics of North America 94: 1127-1139, x.
4. Association AP, (2000) Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. Amer Psychiatric Pub, 4th edition.
5. Denys D, de Geus F, (2005) Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiatry Rep 7: 252-257.
6. Hirschfeld RMA, (2003) Long-term side effects of SSRIs: sexual dysfunction and weight gain. The Journal of Clinical Psychiatry 64 (Suppl 18): 20-24.
7. Lydiard RB, (2003) The role of gaba in anxiety disorders. J Clin Psychiatry 64 (Suppl 3): 21-27.
8. Ravindran LN, Stein MB, (2010) The pharmacologic treatment of anxiety disorders: a review of progress. The Journal of Clinical Psychiatry 71: 839-854.
9. Hochman DW, Baraban SC, Owens JW, Schwartzkroin PA, (1995) Dissociation of synchronization and excitability in furosemide blockade of epileptiform activity. Science (New York, NY) 270: 99-102.
10. Russell JM, (2000) Sodium-potassium-chloride cotransport. Physiological Reviews 80: 211-276.
11. Blaesse P, Airaksinen MS, Rivera C, Kaila K, (2009) Cation-chloride cotransporters and neuronal function. Neuron 61: 820-838.
12. Deisz RA, Lehmann T, Horn P, Dehnicke C, Nitsch R, (2011) Components of neuronal chloride transport in rat and human neocortex. The Journal of Physiology 589: 1317-1347.
13. Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, et al. (2005) NKCC1 transporter facilitates seizures in the developing brain. Nature Medicine 11: 1205-1213.
14. Hesdorffer DC, Stables JP, Hauser WA, Annegers JF, Cascino G, (2001) Are certain diuretics also anticonvulsants? Annals of Neurology 50: 458-462.
15. Ahmad S, Clarke L, Hewett AJ, Richens A, (1976) Controlled trial of frusemide as an antiepileptic drug in focal epilepsy. British Journal of Clinical Pharmacology 3: 621-625.
16. Haglund MM, Hochman DW, (2005) Furosemide and mannitol suppression of epileptic activity in the human brain. Journal of Neurophysiology 94: 907-918.
17. Rudolph U, Knoflach F, (2011) Beyond classical benzodiazepines: novel therapeutic potential of gabaa receptor subtypes. Nat Rev Drug Discov 10: 685-697.
18. Chen H, Sun D, (2005) The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res 27: 280-286.
19. Jayakumar AR, Norenberg MD, (2010) The Na-K-Cl co-transporter in astrocyte swelling. Metab Brain Dis 25: 31-38.
20. MacVicar BA, Feighan D, Brown A, Ransom B, (2002) Intrinsic optical signals in the rat optic nerve: role for K(+) uptake via NKCC1 and swelling of astrocytes. Glia 37: 114-123.
21. Farrant M, Kaila K, (2007) The cellular, molecular and ionic basis of gaba(a) receptor signalling. Prog Brain Res 160: 59-87.
22. Thompson SM, (1994) Modulation of inhibitory synaptic transmission in the hippocampus. Prog Neurobiol 42: 575-609.
23. Khirug S, Yamada J, Afzalov R, Voipio J, Khiroug L, et al. (2008) GABAergic depolarization of the axon initial segment in cortical principal neurons is caused by the Na-K-2Cl cotransporter NKCC1. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 28: 4635-4639.
24. Szabadics J, Varga C, Molnár G, Oláh S, Barzó P, et al. (2006) Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science 311: 233-235.
25. Pain L, Launoy A, Fouquet N, Oberling P, (2002) Mechanisms of action of midazolam on expression of contextual fear in rats. British Journal of Anaesthesia 89: 614-621.
26. Resstel LBM, Joca SRL, Moreira FA, Corra FMA, Guimares FS, (2006) Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behavioural Brain Research 172: 294-298.
27. Hijzen TH, Houtzager SW, Joordens RJ, Olivier B, Slangen JL, (1995) Predictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs. Psychopharmacology 118: 150-154.
28. Joordens RJ, Hijzen TH, Peeters BW, Olivier B, (1996) Fear-potentiated startle response is remarkably similar in two laboratories. Psychopharmacology 126: 104-109.
29. Walf AA, Frye CA, (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols 2: 322-328.
30. Prut L, Belzung C, (2003) The open field as a paradigm to measure the effects of drugs on anxietylike behaviors: a review. European Journal of Pharmacology 463: 3-33.
31. Schwartzkroin PA, Baraban SC, Hochman DW, (1998) Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Research 32: 275-285.
32. Evans MG, Marty A, Tan YP, Trautmann A, (1986) Blockage of ca-activated cl conductance by furosemide in rat lacrimal glands. Pflugers Arch 406: 65-68.
33. Jennings ML, (1985) Kinetics and mechanism of anion transport in red blood cells. Annu Rev Physiol 47: 519-533.
34. Hochman DW, Schwartzkroin PA, (2000) Chloride-cotransport blockade desynchronizes neuronal discharge in the "epileptic" hippocampal slice. Journal of Neurophysiology 83: 406-417.
35. Andreasen F, Tietze I, Hansen FA, Petersen JS, Christensen S, et al. (1991) Furosemide kinetics and dynamics in rats and humans. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology 100: 635-641.
36. Schwartz MA, (1981) Metabolism of bumetanide. Journal of Clinical Pharmacology 21: 555-563.
37. Brater DC, Chennavasin P, Day B, Burdette A, Anderson S, (1983) Bumetanide and furosemide. Clin Pharmacol Ther 34: 207-213.
38. Calabrese EJ, (2008) An assessment of anxiolytic drug screening tests: hormetic dose responses predominate. Critical Reviews in Toxicology 38: 489-542.
39. Brater DC, (1992) Clinical pharmacology of loop diuretics in health and disease. European Heart Journal 13 Suppl G pp. 10-14.
40. Wargo KA, Banta WM, (2009) A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother 43: 1836-1847.
41. Stewart J, (1984) Tested Studies for Laboratory Teaching, Kendall/Hunt, chapter Vascular Cannulation of the Rat pp. 13-20.
42. Lehmann H, Lacanilao S, Sutherland RJ, (2007) Complete or partial hippocampal damage produces equivalent retrograde amnesia for remote contextual fear memories. Eur J Neurosci 25: 1278-1286.
43. Lehmann H, Sparks FT, O'Brien J, McDonald RJ, Sutherland RJ, (2010) Retrograde amnesia for fear-potentiated startle in rats after complete, but not partial, hippocampal damage. Neuroscience 167: 974-984.
44. Muhammad A, Kolb B, (2011) Mild prenatal stress-modulated behavior and neuronal spine density without affecting amphetamine sensitization. Dev Neurosci 33: 85-98.
45. Clark BJ, Hines DJ, Hamilton DA, Whishaw IQ, (2005) Movements of exploration intact in rats with hippocampal lesions. Behav Brain Res 163: 91-99.
46. Davis M, (2001) Fear-potentiated startle in rats. Current Protocols in Neuroscience/Editorial Board, Jacqueline N Crawley, et al. Chapter 8: Unit 8.11A.
47. Montezinho LP, Miller S, Plath N, Jensen NH, Karlsson J, et al. (2010) The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine. Psychopharmacology 212: 131-143.
48. Santos JM, Martinez RCR, Brando ML, (2006) Effects of acute and subchronic treatments with fluoxetine and desipramine on the memory of fear in moderate and high-intensity contextual conditioning. European Journal of Pharmacology 542: 121-128.
49. Fendt M, Fanselow MS, (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neuroscience and Biobehavioral Reviews 23: 743-760.
50. Hogg S, (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, Biochemistry, and Behavior 54: 21-30.
51. Pinheiro SH, Zangrossi J Hlio, Del-Ben CM, Graeff FG, (2007) Elevated mazes as animal models of anxiety: effects of serotonergic agents. Anais Da Academia Brasileira de Cincias 79: 71-85.
52. Stein DJ, Ipser JC, Seedat S, (2006) Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews (Online) CD002795.